Citigroup
BIOL

Citigroup’s Biolase, Inc. BIOL Stock Holding History

Citigroup’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20
Closed -$561 – 5787
2023
Q1 		$561 Buy
+20
New +$973 ﹤0.01% 5196
2016
Q2 		– Hold
0
– -$1K – 7510
2016
Q1 		– Hold
0
– – – 7351
2015
Q4 		– Hold
0
– – – 7924
2015
Q2 		– Hold
0
– – – 7809
2015
Q1 		– Hold
0
– – – 7488
2014
Q4 		– Hold
0
– -$3K – 7370
2014
Q3 		– Hold
0
– – – 6749
2014
Q2 		– Sell
-1
Closed -$25.5K – 6332
2014
Q1 		$18K Hold
1
– – ﹤0.01% 6091
2013
Q4 		$47K Buy
+1
New +$23.7K ﹤0.01% 5754
2013
Q3 		– Hold
0
– – – 6701
2013
Q2 		– Hold
0
– – – 6404

Other funds holding BIOL

Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
APP
Avantax Planning Partners Dubuque, Iowa $3.64B AUM 14.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ZF
Zhang Financial Portage, Michigan $2.89B AUM 18.44% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Citigroup's BIOL Position: Q2 2023 in Review

Citigroup sold out of Biolase, Inc. (BIOL) in Q2 2023, closing a stake of 20 shares — an estimated $561 sold.

Citigroup first reported a position in BIOL in Q4 2013 and held it in 3 quarters. The position peaked at $47K in Q4 2013. 25 funds tracked by Wall St. Rank hold BIOL as of Q2 2023.

  • Citigroup reported no remaining Biolase, Inc. position as of Q2 2023 after selling out during the quarter.
  • Citigroup sold 20 Biolase, Inc. shares in Q2 2023, an estimated $561.
  • Citigroup first reported a position in Biolase, Inc. in Q4 2013 and held it in 3 quarters.
  • Citigroup's Biolase, Inc. position peaked at $47K in Q4 2013.
  • 25 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2023.

Based on Citigroup's 13F filing for Q2 2023, filed 10 Aug 2023.